-
2024-513862-20-00
5
2025-03-26
Chronic Rhinosinusitis with Nasal Polyposis
-
2024-513285-19-00
1
2025-03-14
Pancreatic Ductal Adeno Carcinoma
-
2024-515252-20-00
9
2025-03-14
Myelofibrosis (MF) unresponsive to JAK inhibitors
-
2024-513443-93-00
4
2025-03-10
Recurrent Meningioma without local treatment options (Surgery or Radio
-
2023-506288-33-00
9
2025-03-03
Metastatic castration resistant prostate cancer (mCRPC)
-
2023-508591-11-00
5
2025-02-25
Metastatic breast cancer
-
2024-514333-37-00
4
2025-02-25
Advanced Metastatic Ocular/Uveal Melanoma
-
2024-514306-31-00
5
2025-02-13
Pyoderma gangrenosum
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-513128-40-00
4
2025-02-06
Multifocal Motor Neuropathy
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus
-
2023-505077-32-00
5
2025-01-28
Locally-advanced or metastatic non-squamous non-small cell lung cancer
-
2024-515934-34-00
6
2025-01-28
Low-cardiac output syndrome (LCOS)
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c
-
2024-519310-31-00
4
2025-01-27
Anemia due to MDS with del5q with IPSS-R very low, low, or intermediat
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2024-513852-13-00
5
2025-01-20
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
-
2023-503675-24-00
5
2025-01-17
Triple-negative Breast Cancer
-
2023-508741-40-00
10
2025-01-14
Non-small cell lung cancer
-
2024-512415-45-00
3
2025-01-14
Advanced B cell Non-Hodgkin Lymphomas